Day One Biopharmaceutical... (DAWN)
| Bid | 6.56 |
| Market Cap | 730.26M |
| Revenue (ttm) | 131.16M |
| Net Income (ttm) | -95.5M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -7.06 |
| Forward PE | -11.55 |
| Analyst | Buy |
| Ask | 7.95 |
| Volume | 807,243 |
| Avg. Volume (20D) | 1,190,862 |
| Open | 7.29 |
| Previous Close | 7.12 |
| Day's Range | 6.84 - 7.33 |
| 52-Week Range | 6.41 - 18.07 |
| Beta | -1.25 |
About DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral s...
Analyst Forecast
According to 7 analyst ratings, the average rating for DAWN stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 344.14% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
1 month ago · seekingalpha.com
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call TranscriptDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendi...
